HPV prevalence by age and method of HPV DNA detection (PCR=BS-RLB, HPV6/11 and HPV 16/18 were detected by means of BS-RLB).

<p>HPV prevalence by age and method of HPV DNA detection (PCR=BS-RLB, HPV6/11 and HPV 16/18 were detected by means of BS-RLB).</p

HPV prevalence in precancerous lesions of different anatomical locations.

<p>CIN1 = cervical intraepithelial neoplasia grade 1, CIN2/3 =  cervical intraepithelial neoplasia grade 2 and 3, VIN = vulvar intraepithelial neoplasia.</p>#<p>samples HPV 16 and/or 18 positive.</p><p>*samples which do not contain HPV 16 and/or 18.</p><p>**samples which do not contain HPV 16 and/or 18 and/or 31 and/or 45.</p><p>***samples which do not contain HPV 16 and/or 18.</p

Comparison of overall and type-specific HPV prevalence between CIN1 and SCC, CIN2 and SCC, and CIN3 and SCC cases.

<p>95%CI = 95% confidence interval, RR =  relative risk, P =  probability.</p><p>**all HPV types detected (LR and HR).</p><p>***all HR HPV types detected.</p><p>****HR HPV types 16, 18, 31, 33, 45, 56, and 58.</p

Cumulative percentages of cancer cases of women and men in the Czech Republic.

<p>Cumulative percentages of cervical (A), vulvar (B) and anal (C) cancer cases in women and men occurring every year in the Czech Republic that are attributed to eight most prevalent HPV types (990, 189 and 121 incident cancer cases, respectively). (Sdapted from Munoz, 2004)[46].</p

HPV prevalence in carcinomas of different anatomical locations.

<p>SCC = squamous cell cervical carcinoma, VC = vulvar carcinoma, AC = squamous cell anal carcinoma.</p>#<p>samples HPV 16 and/or 18 positive.</p><p>*samples which do not contain HPV 16 and/or 18.</p><p>**samples which do not contain HPV 16 and/or 18 and/or 31 and/or 45.</p><p>***samples which do not contain HPV 16 and/or 18.</p

HPV prevalence in condyloma acuminata of different anatomical locations.

<p>VCA  =  vulvar condyloma acuminatum, ACA  =  anal condyloma acuminatum.</p>#<p>samples HPV 16 and/or 18 positive.</p><p>*samples which do not contain HPV 16 and/or 18.</p><p>**samples which do not contain HPV 16 and/or 18 and/or 31 and/or 45.</p><p>***samples which do not contain HPV 16 and/or 18.</p

Additional file 10: Figure S4. of Comparison of the miRNA profiles in HPV-positive and HPV-negative tonsillar tumors and a model system of human keratinocyte clones

Expression values of miRNAs differentially expressed in HPV-positive tonsillar tumors on miRNA arrays. Fold change >1.33, P-value <0.05. HPV-positive tonsillar tumors (HPV+ TT), normal tonsils (NT), HPV-immortalized keratinocytes clones (tHFK), primary keratinocytes clones (pHFK). (DOC 166 kb